

Priorities for reform for the innovative medicines and vaccines industry

Three critical priority areas must be addressed to secure the future of our industry, cement our position on the global stage, and ensure timely access to lifesaving medicines for all Australians.



Global Access Pressures

Secure Australia's position as a global player in health and innovative medicine

Given the challenging global dynamics of international reference pricing¹, it's harder than ever to develop, deliver and ensure access to innovative medicines.

Changes to Australia's HTA process are critical to ensure Australia remains the first-wave launch country. This will help avoid access delays, prioritise innovation in health, and ensure preparedness for future pandemics.



Patient Partnerships

Give patients a greater ability to contribute and be heard

Ensure our health system acknowledges the needs of patients and their carers earlier in the HTA review process so that their expectations are met.



Broader Value

Strengthen Australia's HTA process to ensure timely access to innovative medicines for patients

Our HTA system must evolve to be in closer alignment with international best-practices, and to recognise the broader value of innovative medicines for patients and the economy.

There must be more first-time approvals, greater process efficiencies, and faster access.

For further information on these issues please visit our website www.medicinesaustralia.com.au

¹ International reference pricing is a pricing mechanism whereby a government considers the price of a medicine in other countries to inform or establish the price in its own country. The United States has signalled its intention to introduce international reference pricing and China has already done so.